LONDON - IXICO plc (AIM: IXI), a data analytics company specializing in neuroimaging, announced today the securement of a contract with a U.S.-based client to provide imaging services for a Phase 2 clinical trial targeting Huntington's Disease. The contract, valued at over £0.5 million, is set to span roughly 2.5 years and represents a continuation of the company's commercial growth, as noted in its FY24 Final Results.
Huntington's Disease, a rare genetic neurodegenerative disorder, progressively impairs the brain's nerve cells, affecting motor skills and cognitive functions. IXICO's role in the trial underscores its commitment to advancing research in neurological disorders, leveraging its AI-driven platform.
Bram Goorden, CEO of IXICO, expressed the company's pride in contributing to the Huntington's Disease community and the pursuit of effective treatments. He emphasized IXICO's position as a trusted partner in neurodegenerative disease trials and its alignment with the company's strategic goals of innovation, leadership, and scaling for growth.
This new contract adds to a series of agreements IXICO has secured throughout 2024, expanding its involvement in clinical trials across various neurological conditions, including Parkinsonian Disorders and Alzheimer's Disease.
IXICO's expertise in medical image analysis is a critical component in supporting pharmaceutical clients in CNS clinical research, aiming to enhance the efficiency and reliability of drug development processes.
The announcement of this contract is considered public information as per the UK version of the EU Market Abuse Regulation. The company's purpose and ongoing efforts are to transform data into clinically meaningful insights, aiding in the progression of treatments for neurological diseases.
This contract win is based on a press release statement and reflects IXICO's current business trajectory and its contributions to the field of neuroscience.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.